Effects of enalapril versus placebo as a treatment for canine idiopathic glomerulonephritis

Journal of veterinary internal medicine / American College of Veterinary Internal Medicine

Volumn 14, Issue 5, 2000, Pages 526-533

  Grauer, Gregory F ^a   Greco, Deborah S ^a   Getzy, David M ^b   Cowgill, Larry D ^c   Vaden, Shelly L ^d   Chew, Dennis J ^e   Polzin, David J ^f   Barsanti, Jeanne A ^g  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b IDEXX Veterinary Services Laboratory   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NORTH CAROLINA STATE UNIVERSITY   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL; ANIMAL DISEASE; ARTICLE; BIOPSY; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; GLOMERULONEPHRITIS; KIDNEY; MULTICENTER STUDY; PATHOLOGY; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; URINE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BIOPSY; BLOOD PRESSURE; CREATININE; DOG DISEASES; DOGS; ENALAPRIL; GLOMERULONEPHRITIS; KIDNEY; PROSPECTIVE STUDIES; PROTEINURIA;

EID: 0034277440     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2000.tb02271.x     Document Type: Article

References (37)

1. 1 MacDougall DF, Cook T., Steward AP, et al. Canine chronic renal disease: Prevalence and types of glomerulonephritis in the dog. Kidney Int 1986 ; 29: 1144–1151.
2. 2 Center SA, Smith CA, Wilkinson E., et al. Clinicopathologic, renal immunofluorescent, and light microscopic features of glomerulonephritis in the dog: 41 cases. J Am Vet Med Assoc 1987 ; 190: 81–90.
3. 3 Jerums G., Panagiotopoulos S., Tsalamandris C., et al. Why is proteinuria such an important risk factor for progression in clinical trials Kidney Int 1997 ; 52: S87–S92.
4. 4 Tang S., Sheerin NS, Zhou W., et al. Apical proteins stimulate complement synthesis by cultured human proximal tubular epithelial cells. J Am Soc Nephrol 1999 ; 10: 69–76.
5. 5 Cook AK, Cowgill LD. Clinical and pathological features of protein‐losing glomerular disease in the dog—A review of 137 cases (1985–1992). J Am Anim Hosp Assoc 1996 ; 32: 313–322.
6. 6 Vaden SL, Breitschwerdt EB, Armstrong JP, et al. The effects of cyclosporin versus standard care in dogs with naturally occurring glomerulonephritis. J Vet Int Med 1995 ; 9: 259–266.
7. 7 Maschio G., Alberti D., Janin G., et al. Effects of the angiotensinconverting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996 ; 334: 939–945.
8. 8 Ihle BU, Whitworth JA, Shahinfar S., et al. Angiotensin‐converting enzyme inhibition in nondiabetic progressive renal insufficiency: A controlled double‐blind trial. Am J Kidney Dis 1996 ; 27: 489–495.
9. 9 Apperloo AJ, de Zeeuw D., De Jong PE. Short‐term antiproteinuric response to antihypertensive treatment predicts long‐term GFR decline in patients with non‐diabetic renal disease. Kidney Int 1994 ; 45: S174–S178.
10. 10 Gansevoort RT, de Zeeuw D., de Jong PE. Long‐term benefits of the antiproteinuric effect of angiotensin‐converting enzyme inhibition in nondiabetic renal disease. Am J Kidney Dis 1993 ; 22: 202–206.
11. 11 Brown SA, Walton CL, Crawford P., et al. Long‐term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int 1993 ; 43: 1210–1218.
12. 12 Grodecki KM, Gains MJ, Baumal R., et al. Treatment of X‐linked hereditary nephritis in Samoyed dogs with angiotensin converting enzyme (ACE) inhibitor. J Comp Pathol 1997 ; 117: 209–225.
13. 13 Ruggenenti P., Perna A., Benini R., et al. In chronic nephropathies prolonged ACE inhibition can induce remission: Dynamics of time‐dependent changes in GFR. J Am Soc Nephrol 1999 ; 10: 997–1006.
14. 14 Pedersen EB, Bech JN, Nielsen CB, et al. A comparison of the effect of ramipril, felodipine and placebo on glomerular filtration rate, albuminuria, blood pressure and vasoactive hormones in chronic glomerulonephritis. Scand J Clin Lab Invest 1997 ; 57: 673–681.
15. 15 Yanagawa N., Capparelli AD, Jo OD, et al. Production of angiotensin and renin‐like activity by rabbit proximal tubular cells in culture. Kidney Int 1991 ; 39: 938–941.
16. 16 Yamada H., Sexton P., Chai S., et al. Angiotensin II receptors in the kidney: Localization and physiologic significance. Am J Hypertens 1990 ; 3: 250–255.
17. 17 Carmines P., Perry M., Hazelrig J., et al. Effects of preglomerular and postglomerular vascular resistance alterations on filtration fraction. Kidney Int 1987 ; 20: S229–S232.
18. 18 Raij L., Keane W. Glomerular mesangium: Its function and relationship to angiotensin II. Am J Med 1985 ; 79 (Suppl 3C): 24–30.
19. 19 Nakamura T., Obata J., Kimura H., et al. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Kidney Int 1999 ; 55: 877–889.
20. 20 Hamlin RL, Nakayama T. Comparison of some pharmacokinetic parameters of 5 angiotensin‐converting enzyme inhibitors in normal beagles. J Vet Intern Med 1998 ; 12: 93–95.
21. 21 Erhley CM, Harrer U., Kramer B., et al. Renal hemodynamics and reduction of proteinuria by a vasodilating beta‐blocker versus an ACE inhibitor. Kidney Int 1992 ; 41: 1297–1303.
22. 22 Reddi AS, Ramamurthi R., Miller M., et al. Enalapril improves albuminuria by preventing glomerular loss of heparan sulfate in diabetic rats. Biochem Med Metab Biol 1991: 45: 119–131.
23. 23 Morelli E., Loon N., Meyer T., et al. Effects of converting‐enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 1990 ; 39: 76–82.
24. 24 Wiegmann TB, Herron KG, Chonko AM, et al. Effect of angiotensin‐converting enzyme inhibition on renal function and albuminuria in normotensive type I diabetic patients. Diabetes 1992 ; 41: 62–67.
25. 25 Keilani T., Schlueter WA, Levin ML, et al. Improvement of lipid abnormalities associated with proteinuria using fosinopril, and angiotensin‐converting enzyme inhibitor. Ann Intern Med 1993 ; 118: 246–254.
26. 26 Hutchison FN, Cui X., Webster SK. The antiproteinuric action of angiotensin‐converting enzyme is dependent on kinin. J Am Soc Nephrol 1995 ; 6: 1216–1222.
27. 27 Heller J., Kramer HJ, Horacek V. Comparative effects of the angiotensin II receptor blocker EXP 3174 and of the angiotensin‐converting enzyme inhibitor captopril on renal glomerular hemodynamics in the dog. Kidney Blood Press Res 1997 ; 20: 391–397.
28. 28 Polzin DJ, Osborne CA. The importance of egg protein in reduced protein diets designed for dogs with renal failure. J Vet Int Med 1988 ; 2: 15–21.
29. 29 Ruilope LM, Casal MC, Praga M., et al. Additive antiproteinuric effect of converting enzyme inhibition and a low protein intake. J Am Soc Nephrol 1992 ; 3: 1307–1311.
30. 30 de Jong PE, Anderson S., de Zeeuw D. Glomerular preload and afterload reduction as a tool to lower urinary protein leakage: Will such treatments also help to improve renal function outcome J Am Soc Nephrol 1993 ; 3: 1333–1341.
31. 31 Ikoma M., Kaawamura T., Kakinuma Y., et al. Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 1991 ; 40: 195–202.
32. 32 Verseput GH, Provoost AP, Braam BB, et al. Angiotensin‐converting enzyme inhibition in the prevention and treatment of chronic renal damage in the hypertensive fawn‐hooded rat. J Am Soc Nephrol 1997 ; 8: 249–259.
33. 33 Wapstra FH, Van Goor H., Navis G., et al. Antiproteinuric effect predicts renal protection by angiotensin‐converting enzyme inhibition in rats with established adriamycin nephrosis. Clin Sci 1996 ; 90: 393–401.
34. 34 Toto RD, Mitchell HC, Lee HC, et al. Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med 1991 ; 115: 513–519.
35. 35 Devoy MAB, Tomson CRV, Edmunds ME, et al. Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible. J Intern Med 1992 ; 232: 493–498.
36. 36 Peterson JC, Adler S., Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med 1995 ; 123: 754–762.
37. 37 Ruggenenti P., Perna A., Mosconi L., et al. Urinary protein excretion rate is the best independent predictor of ESRF in non‐diabetic proteinuric chronic nephropathies. Kidney Int 1998 ; 53: 1209–1216.